Literature DB >> 20354544

Imaging: Mass spectrometry in HNSCC--a peek at response prediction?

Mei-Kim Ang1, D Neil Hayes.   

Abstract

EGFR inhibitors provide benefit in patients with advanced and metastatic head and neck squamous cell carcinoma (HNSCC). Mass spectrometry profiling has been used to predict outcome in patients with HNSCC after EGFR inhibitor treatment, and may enable prior identification of patients most likely to benefit from these therapies. however, further validation in prospective studies is needed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20354544     DOI： 10.1038/nrclinonc.2010.35

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

Authors:  Eleftherios P Diamandis
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

Review 2.  Molecular therapy in head and neck oncology.

Authors:  Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

Review 3.  Mass spectrometry-based proteomic profiling of lung cancer.

Authors:  Sebahat Ocak; Pierre Chaurand; Pierre P Massion
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

4.  INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.

Authors:  Ramaswamy Govindan
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

5.  Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

Authors:  Christine H Chung; Erin H Seeley; Heinrich Roder; Julia Grigorieva; Maxim Tsypin; Joanna Roder; Barbara A Burtness; Athanassios Argiris; Arlene A Forastiere; Jill Gilbert; Barbara Murphy; Richard M Caprioli; David P Carbone; Ezra E W Cohen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

6.  Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.

Authors:  Stuart Salmon; Heidi Chen; Shuo Chen; Roy Herbst; Anne Tsao; Hai Tran; Alan Sandler; Dean Billheimer; Yu Shyr; Ju-Whei Lee; Pierre Massion; Julie Brahmer; Joan Schiller; David Carbone; Thao P Dang
Journal:  J Thorac Oncol       Date:  2009-06       Impact factor: 15.609

Review 7.  Mechanisms of resistance to EGFR inhibitors in head and neck cancer.

Authors:  Jonathan B Cooper; Ezra Eddy Wyssam Cohen
Journal:  Head Neck       Date:  2009-08       Impact factor: 3.147

8.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Authors:  Fumiko Taguchi; Benjamin Solomon; Vanesa Gregorc; Heinrich Roder; Robert Gray; Kazuo Kasahara; Makoto Nishio; Julie Brahmer; Anna Spreafico; Vienna Ludovini; Pierre P Massion; Rafal Dziadziuszko; Joan Schiller; Julia Grigorieva; Maxim Tsypin; Stephen W Hunsucker; Richard Caprioli; Mark W Duncan; Fred R Hirsch; Paul A Bunn; David P Carbone
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

9.  VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

Authors:  David P Carbone; J Stuart Salmon; Dean Billheimer; Heidi Chen; Alan Sandler; Heinrich Roder; Joanna Roder; Maxim Tsypin; Roy S Herbst; Anne S Tsao; Hai T Tran; Thao P Dang
Journal:  Lung Cancer       Date:  2009-12-29       Impact factor: 5.705

10.  Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

Authors:  Joseph M Amann; Ju-Whei Lee; Heinrich Roder; Julie Brahmer; Adriana Gonzalez; Joan H Schiller; David P Carbone
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.